תאריך רישום: March 27, 2024

מסלול הגשה: מולקולה חדשה

יצרן: ELI LILLY AND COMPANY, USA

בעל רישום: ELI LILLY ISRAEL LTD, ISRAEL

D11AH10 :ATC Code

תאריך רישום: January 29, 2024

מסלול הגשה: מולקולה חדשה

יצרן: ANDERSONBRECON INC., USA

בעל רישום: PFIZER PHARMACEUTICALS ISRAEL LTD

L04AE05 :ATC Code

תאריך רישום: February 4, 1999

מסלול הגשה: מולקולה חדשה

יצרן: MACORS LABORATORIES, FRANCE

בעל רישום: A. LAPIDOT PHARMACEUTICALS LTD, ISRAEL

G03XB01 :ATC Code

4.1 Therapeutic Indications 1) Medical termination of developing intra-uterine pregnancy. In sequential use with a prostaglandin analogue, up to 63 days of amenorrhea. 2) Softening and dilatation of the cervix uteri prior to surgical termination of pregnancy during the first trimester. 3) Preparation for the action of prostaglandin analogues in the termination of pregnancy for medical reasons (beyond the first trimester) 4) Labour induction in foetal death in utero. In patients where prostaglandin or oxytocin cannot be used.

תאריך רישום: April 15, 2007

מסלול הגשה: מולקולה חדשה

יצרן: MAX ZELLER SOHNE AG, SWITZERLAND

בעל רישום: RAFA LABORATORIES LTD

:ATC Code

4.1. Therapeutic Indications For the treatment of symptoms of mild to moderate depression including dejected mood, mood lability, anxiety, inner restlessness, states of tension, and difficulty in falling asleep and sleeping through the night which is associated with these conditions. Treatment is recommended for up to 24 weeks.

תאריך רישום: February 7, 2008

מסלול הגשה: מולקולה חדשה

יצרן: JANSSEN CILAG S.P.A, ITALY

בעל רישום: J-C HEALTH CARE LTD

J05AG04 :ATC Code

4.1 Therapeutic indications INTELENCE, in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients, including those with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance. Treatment history and, when available, resistance testing, should guide the use of INTELENCE. In patients who have experienced virological failure on an NNRTI- and nucleoside or nucleotide reverse transcriptase inhibitor (N[t]RTI)-containing regimen, INTELENCE is not recommended for use in combination with N(t)RTIs only.

תאריך רישום: June 27, 2017

מסלול הגשה: מולקולה חדשה

יצרן: MILLMOUNT HEALTHCARE LIMITED, IRELAND

בעל רישום: MEDISON PHARMA LTD

L01XC16 :ATC Code

4.1 Therapeutic indications Qarziba is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures. In patients with a history of relapsed/refractory disease and in patients who have not achieved a complete response after first line therapy, Qarziba should be combined with interleukin-2 (IL-2).